Supernus Pharmaceuticals | SUPN - Los Gastos Financieros De La Deuda





Los Gastos Financieros De La Deuda Cambio Fecha
Abbott USD 68M 26M 2026-03
ANI Pharmaceuticals USD 4.41M 316K 2025-12
Aurora Cannabis CAD 2.11M 116K 2025-12
Bristol-Myers Squibb USD 411M 21M 2026-03
Canopy Growth CAD 7.34M 1.46M 2025-12
Cara Therapeutics -89.64M 128.67M 2025-12
Corcept Therapeutics USD 814.88M 809.46M 2026-03
Eisai JPY 1.55B 117M 2026-03
Eli Lilly USD 114.7M 134.3M 2025-09
Novo Nordisk DKK 1.53B 3.43B 2025-09
Pacira USD 3.7M 193K 2026-03
Perrigo USD 7.98B 7.94B 2026-03
Pfizer USD 671M 40M 2026-03
Supernus Pharmaceuticals USD 910K 278K 2023-06
United Therapeutics USD 3.1M 100K 2025-12
Xeris Pharmaceuticals USD 7.15M 115K 2025-12